|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Nanjing Medical University |
|---|---|
| Information provided by: | Nanjing Medical University |
| ClinicalTrials.gov Identifier: | NCT00815269 |
Purpose
Previous studies on animals suggest that inhalational anesthetics can reduce vascular tension in vitro resulting in vasodilation and decrease in blood pressure. This role for inhalational anesthetics has essential clinical implications such as the condition of sepsis or septic shock or other shock-associated states during which the blood vessel constricts strongly and leads to circulation dysfunction. The vasodilation property of these anesthetics including halothane, isoflurane, sevoflurane, desflurane and enflurane enables them to be better options than other general anesthetics in many clinical conditions needing the vasculature to be dilated. The investigators hypothesized that these inhalational anesthetics can evoke vasodilation measured with ultrasonography during general anesthesia in vivo as the in vitro studies displayed.
| Condition | Intervention |
|---|---|
|
General Anesthesia |
Drug: Halothane Drug: Isoflurane Drug: Sevoflurane Drug: Desflurane Drug: Enflurane |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Vasodilation Effect of Inhalational Anesthetics Including Halothane, Isoflurane, Sevoflurane, Desflurane and Enflurane |
| Enrollment: | 300 |
| Study Start Date: | December 2008 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Halothane anesthesia: induction and maintenance with different doses
|
Drug: Halothane
Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
Other Name: Fluothane
|
|
Experimental: 2
Isoflurane anesthesia: induction and maintenance with different doses
|
Drug: Isoflurane
Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
Other Name: Forane
|
|
Experimental: 3
Sevoflurane anesthesia: induction and maintenance with different doses
|
Drug: Sevoflurane
Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
Other Name: Sevorane
|
|
Experimental: 4
Desflurane anesthesia: induction and maintenance with different doses
|
Drug: Desflurane
Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
Other Name: Suprane
|
|
Experimental: 5
Enflurane anesthesia: induction and maintenance with different doses
|
Drug: Enflurane
Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
Other Name: Ethrane
|
Eligibility| Ages Eligible for Study: | 19 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| China, Jiangsu | |
| Nanjing Maternal and Child Health Care Hospital | |
| Nanjing, Jiangsu, China, 210004 | |
| Study Director: | XiaoFeng Shen, MD | Nanjing Medical University |
More Information
| Responsible Party: | XiaoFeng Shen, Nanjing Medical University |
| ClinicalTrials.gov Identifier: | NCT00815269 History of Changes |
| Other Study ID Numbers: | NMU-200812-MZ39, NJFY0812015 |
| Study First Received: | December 26, 2008 |
| Last Updated: | December 22, 2009 |
| Health Authority: | China: Ethics Committee |
|
Inhalant anesthetic Vasodilation General anesthesia Ultrasonography |
|
Anesthetics Enflurane Halothane Isoflurane Desflurane Sevoflurane Anesthetics, Inhalation Central Nervous System Depressants |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anesthetics, General Platelet Aggregation Inhibitors Hematologic Agents |